A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF).

Project: Research project

Project Details

StatusFinished
Effective start/end date10/17/17 → 4/30/22

Funding

  • Boehringer Ingelheim Pharmaceuticals ( Award # ): $10,500.00